Physician profile
Paul N Siebert
NPI 1619395191
$1,276.66
in general payments reported to CMS, 2019-2025
13 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.78 · 2020: $165 · 2021: $93.45 · 2022: $276 · 2023: $146 · 2024: $256 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.41 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $538.71 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $158.03 | 2020-2025 | Zerbaxa |
| Abbvie INC. | $156.59 | 2021-2025 | Dalvance |
| Viiv Healthcare Company | $154.35 | 2023-2025 | Apretude, Dovato |
| Shionogi INC | $99.78 | 2022-2023 | Fetroja |
| Allergan, INC. | $38.15 | 2020 | |
| Melinta Therapeutics, LLC | $24.81 | 2020 | |
| La Jolla Pharmaceutical Company | $24.18 | 2022 | |
| Octapharma USA, INC. | $19.59 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.48 | 2024 | Nuzyra |
| Aimmune Therapeutics, INC. | $15.54 | 2025 | Vowst |
| Insmed, INC. | $15.25 | 2022 | |
| Janssen Biotech, INC. | $14.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Siebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.